GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Total Current Liabilities

VRAX (Virax Biolabs Group) Total Current Liabilities : $0.69 Mil (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Virax Biolabs Group's total current liabilities for the quarter that ended in Sep. 2024 was $0.69

Virax Biolabs Group Total Current Liabilities Historical Data

The historical data trend for Virax Biolabs Group's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Total Current Liabilities Chart

Virax Biolabs Group Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Total Current Liabilities
1.24 0.87 1.25 0.91 0.17

Virax Biolabs Group Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.14 0.91 0.79 0.17 0.69

Virax Biolabs Group Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Virax Biolabs Group's Total Current Liabilities for the fiscal year that ended in Mar. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.121+0.048
+Other Current Liabilities+Current Deferred Liabilities
=2.7755575615629E-17+0
=0.17

Virax Biolabs Group's Total Current Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0.468+0.048
+Other Current Liabilities+Current Deferred Liabilities
=0.178+0
=0.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Virax Biolabs Group Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Total Current Liabilities
Comparable Companies
AEON ADIL ALZN KTTA CPMV AZTR BZYR SXTP CERO XBIO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH
Website
https://www.viraxbiolabs.com
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.